Carlisle Companies Incorporated (CSL)

Return on total capital

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	1,039,100	1,065,900	1,060,700	1,188,300	1,316,100	1,218,200	1,066,700	792,400	600,400	529,200	488,900	467,800	478,200	508,200	546,100	638,500	663,100	636,400	584,900	535,000
Long-term debt	US$ in thousands	1,886,700	2,283,200	2,282,200	2,281,900	2,281,100	2,280,300	2,577,700	2,576,700	2,575,400	2,924,000	2,080,400	2,081,000	2,080,200	2,079,400	2,077,200	2,576,400	1,341,400	1,590,200	1,589,400	1,588,500
Total stockholders’ equity	US$ in thousands	2,829,000	2,923,800	3,032,000	3,058,300	3,024,400	3,041,700	2,875,100	2,678,600	2,629,500	2,544,800	2,417,900	2,411,800	2,537,700	2,475,300	2,516,200	2,518,500	2,642,800	2,681,000	2,583,200	2,524,700
Return on total capital		22.03%	20.47%	19.96%	22.25%	24.81%	22.89%	19.56%	15.08%	11.54%	9.68%	10.87%	10.41%	10.36%	11.16%	11.89%	12.53%	16.64%	14.90%	14.02%	13.01%

December 31, 2023 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $1,039,100K ÷ ($1,886,700K + $2,829,000K)
= 22.03%

The return on total capital for Carlisle Companies Inc. has been relatively stable over the past eight quarters, ranging from a low of 13.42% in Q1 2022 to a high of 23.10% in Q4 2022. The company's performance in Q1 2023 stands out with a return on total capital of 20.60%, a slight decrease from the previous quarter's 19.25%. Overall, Carlisle Companies Inc. has maintained a healthy return on total capital, indicating efficient use of both debt and equity to generate profits.

Peer comparison

Dec 31, 2023

Company name

Symbol

Return on total capital

Carlisle Companies Incorporated

CSL

22.03%

West Pharmaceutical Services Inc

WST

24.53%